- Home
- SAVA vs NXC Comparison
SAVA vs NXC Comparison
Compare SAVA & NXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- NXC
- Stock Information
- Founded
- SAVA 1998
- NXC 1992
- Country
- SAVA United States
- NXC United States
- Employees
- SAVA N/A
- NXC N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- NXC Investment Managers
- Sector
- SAVA Health Care
- NXC Finance
- Exchange
- SAVA Nasdaq
- NXC Nasdaq
- Market Cap
- SAVA 102.4M
- NXC 82.6M
- IPO Year
- SAVA N/A
- NXC N/A
- Fundamental
- Price
- SAVA $2.34
- NXC $12.82
- Analyst Decision
- SAVA Hold
- NXC
- Analyst Count
- SAVA 1
- NXC 0
- Target Price
- SAVA $2.00
- NXC N/A
- AVG Volume (30 Days)
- SAVA 867.7K
- NXC 17.5K
- Earning Date
- SAVA 08-14-2025
- NXC 01-01-0001
- Dividend Yield
- SAVA N/A
- NXC 3.97%
- EPS Growth
- SAVA N/A
- NXC N/A
- EPS
- SAVA N/A
- NXC 0.19
- Revenue
- SAVA N/A
- NXC N/A
- Revenue This Year
- SAVA N/A
- NXC N/A
- Revenue Next Year
- SAVA N/A
- NXC N/A
- P/E Ratio
- SAVA N/A
- NXC $70.47
- Revenue Growth
- SAVA N/A
- NXC N/A
- 52 Week Low
- SAVA $1.15
- NXC $11.86
- 52 Week High
- SAVA $33.98
- NXC $13.70
- Technical
- Relative Strength Index (RSI)
- SAVA 54.06
- NXC 46.94
- Support Level
- SAVA $2.20
- NXC $12.78
- Resistance Level
- SAVA $2.43
- NXC $12.93
- Average True Range (ATR)
- SAVA 0.17
- NXC 0.09
- MACD
- SAVA -0.00
- NXC 0.00
- Stochastic Oscillator
- SAVA 60.42
- NXC 45.83
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.